S
Shengfang Pharmaceutical Research
Technology-based full featured clinical CRO
About Shengfang Pharmaceutical Research
Elixir Clinical Research operates as a contract research organization (CRO) based in Shanghai, China, offering a comprehensive suite of services to the life sciences industry. The company was established in 2019 to address the growing needs of pharmaceutical and medical device enterprises.
The firm specializes in managing the entire clinical trial lifecycle, from bioequivalence (BE) studies and Phase I-IV trials to post-marketing and real-world studies. Its service portfolio includes clinical research program design, medical strategy, regulatory registration and affairs, data management, and biostatistics. Elixir Clinical Research aims to enhance the efficiency of clinical research management by integrating digital technologies, such as AI and big data, into its operations. This approach facilitates a data-driven clinical research model intended to provide more transparent project quality control and accelerate the commercialization process for new drugs.
The company serves pharmaceutical companies by providing solutions designed to bring new drugs to market more quickly. In April 2022, Elixir Clinical Research secured $52 million in a Series A funding round. The round was supported by investors including LYFE Capital, Sinovation Ventures, and Chow Tai Fook Enterprises, indicating confidence in the company's tech-driven approach to clinical trials.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Xuhui District, China
- Open positions
- None listed
- Dealroom signal
- 21.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, Health Platform
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Apr 2022 | $52M | $208M | Chow Tai Fook · Innovation Workshop · LYFE Capital | ↗ |
Growth signals
Latest recorded traffic for Shengfang Pharmaceutical Research is 130 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Chow Tai Fook- IWInnovation Workshop
LYFE Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shengfang Pharmaceutical Research on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shengfang Pharmaceutical Research’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.